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https://doi.org/10.1016/j.stemcr.2017.09.008SUMMARYAccurately predicting cardioactive effects of new molecular entities for therapeutics remains a daunting challenge. Immense research
effort has been focused toward creating new screening platforms that utilize humanpluripotent stem cell (hPSC)-derived cardiomyocytes
and three-dimensional engineered cardiac tissue constructs to better recapitulate humanheart function and drug responses. As these new
platforms become increasingly sophisticated and high throughput, the drug screens result in largermultidimensional datasets. Improved
automated analysismethodsmust therefore be developed in parallel to fully comprehend the cellular response across amultidimensional
parameter space. Here, we describe the use of machine learning to comprehensively analyze 17 functional parameters derived from force
readouts of hPSC-derived ventricular cardiac tissue strips (hvCTS) electrically paced at a range of frequencies and exposed to a library of
compounds. A generated metric is effective for then determining the cardioactivity of a given drug. Furthermore, we demonstrate a clas-
sification model that can automatically predict the mechanistic action of an unknown cardioactive drug.INTRODUCTION
Drugs in late-stage development as well as those with
market approval are often withdrawn due to previously un-
detected drug-induced cardiotoxicity. Unpredicted drug-
induced cardiotoxicity jeopardizes patients’ lives, erodes
public trust in the regulatory process, and financially bur-
dens the pharmaceutical industry. For example, cisapride,
a gastrointestinal drug intended to treat heartburn, was re-
ported to have caused serious ventricular arrhythmias and
sudden deaths prior to withdrawal (Ferriman, 2000). The
associated pharmaceutical company agreed to settle law-
suits for a total of $90 million US dollars for 300 deaths
and 16,000 injuries (Harris and Koli, 2005). Progress has
been made to facilitate better safety through the adoption
of US Food and Drug Administration guidelines that
recommend screening new drugs with the human ether-
a-go-go-related gene (hERG) inhibition assay (FDA, 2005).
Nonetheless, within the past decade, an assortment ofmar-
ket-approved therapeutics (e.g., clobutinol, sibutramine,
and tegaserod) had to be withdrawn due to unpredicted
drug-induced cardiotoxicity (FDA, 2016; Li et al., 2016).
The need for more accurate and faster pre-clinical detec-
tion methods has led to the emergence of a variety of
screening platforms in recent years. A majority of these
detection systems have begun to utilize human pluripotent
stem cell-derived cardiomyocytes (hPSC-CMs). These cells1560 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017 j ª 2017
This is an open access article under the CC BY-NC-ND license (http://creativare more physiologically similar to human myocardium
than laboratory animals or genetically transformed non-
cardiac cell lines (e.g., human embryonic kidney cells)
(Dick et al., 2010). Aside from the commonality of using
hPSC-CMs, these platforms vary greatly in their setup,
including differences in tissue geometry. Certain platforms
employ hPSC-CMs in a two-dimensional manner (e.g.,
monolayer), while others attempt to recapitulate aspects
of the three-dimensional environment of native myocar-
dium bymodeling the cells as cardiacmuscle fibers or heart
chambers (Chen et al., 2014; Huebsch et al., 2016; Lee et al.,
2008). These systems can also differ drastically in their
methodology of quantifying changes in hPSC-CMs
exposed to cardioactive compounds. Some systems
examine the electrophysiological properties while others
focus on the calcium transients or measurements of
contractility (e.g., shortening, force, pressure) generated
by the cardiomyocytes (Lu et al., 2015; Maddah et al.,
2015; Navarrete et al., 2013; Zhang et al., 2014).
While the experimental platformsmay vary, quantitative
readouts generally characterize individual contractile
events. Combining this with the number of experimental
conditions (e.g., various pacing frequencies or drug con-
centrations) can yield large multidimensional datasets
that make it difficult to draw thorough conclusions.
Researchers often simplify the raw data by preselecting
a limited number of parameters as an attempt toThe Authors.
ecommons.org/licenses/by-nc-nd/4.0/).
comprehend the complexity of the data, albeit losing infor-
mation in the process.Without full interpretation of such a
rich dataset, there is a risk of not detecting information that
differentiates the behavior of normal hPSC-CMs from
those exposed to cardioactive compounds. In addition, as
these platforms are meant for high-content screens, the
analysis of the datasets needs to be automated.
Holistic approaches must be developed to optimize the
utility of datasets generated from screening platforms.
Machine learning has been shown to handle such multidi-
mensional datasets in an automated fashion (Lee et al.,
2015). We previously demonstrated that support vector
machine (SVM), a supervised learning algorithm, can be
used to consolidate 12 parameters, which characterize the
contractile behavior of hPSC-CMs exposed to cardioactive
compounds, into a singular quantitative index that
expresses the level of induced cardioactivity (Lee et al.,
2015). Machine learning can be further leveraged into a
suite of tools that provide more in-depth details of hPSC-
CM behavior when exposed to cardioactive compounds.
In this study, we hypothesize that multiclassification algo-
rithms can be implemented to create amodel to define drug
classes and subsequently predict an unknown compound’s
mechanistic action. Such information would assist in
streamlining the drug discovery pipeline, allowing for the
rapid identification of select compounds for more in-depth
follow-up assays. In addition, this information coupled
with knowledge of predicted class can guide scientists to
efficiently and selectively screen for specific drug-to-drug
interactions that prompt cardiotoxicity (e.g., disruption
of Ca2+ handling when sofosbuvir and amiodarone are
combined) instead of relying on the traditional brute force
approach (Millard et al., 2016). Furthermore, drug-
response relationships between the unknown compound
and the library can be determined.
To test our hypothesis, we examined a database (not yet
published) containing drug screens of various compounds
on twitch forcemeasurements fromhuman ventricular car-
diac tissue strips (hvCTS) engineered from hPSC-CMs
embedded in a 3D collagen-based matrix (Turnbull et al.,
2014). A unique aspect of these screens was that the
hvCTSs were electrically paced at four different frequencies
from 0.5 to 2.0 Hz, spanning a physiological range. These
measurements interrogated the influence of cardioactive
compounds on the hvCTS force-frequency relationship
and contributed to a multidimensional dataset. We
selected a total of 12 compounds with acute cardiac effects
that represented five drug classes (1, Ca2+ channel blockers;
2, adrenergic agonists; 3, cardiac glycosides; 4, hERG K+
channel blockers; and 5, angiotensin-converting enzyme
[ACE] inhibitors) along with one reference compound
(aspirin). In this study, we report the use of machine
learning to establish a drug classification model based onhvCTS contractile behavior (using half of the selected com-
pounds) and subsequently demonstrate predictive capabil-
ities by having the model classify unknown compounds,
which were withheld from the machine during training.RESULTS
Formation of the Drug Classification Model
To form the drug classification model, the screens of 12
compounds (Table 1) acquired on the hvCTS platform
were used. Each of the compounds, with the exception of
aspirin, belonged to one of five classes with each class
comprising a minimum of two compounds. Aspirin func-
tioned as a reference for a cardiac-neutral compound. To
quantify the cardioactive effects of these compounds, a
total of 17 parameters were derived from each contractile
event recorded in the hvCTS twitch force versus time trac-
ings (Figure S1). Once the parameters characterizing each
contraction were calculated, establishing the library with
machine learning consisted of two primary steps. The first
step was determining the degree of cardioactivity for each
compound at a given dosage by calculating a singular
quantitative index generated by a binary SVM approach
(Figure 1A). The second step involved multiclass SVM to
establish the boundaries that represent each drug class
(Figure 1B).
The binary SVM is capable of summarizing all parameters
and providing a simplemetric that expresses a compound’s
degree of cardioactivity at a given dosage (Lee et al., 2015).
Specifically, the machine is tasked with creating a decision
boundary that separates two groups (data from untreated
hvCTSs and those fromhvCTSs exposed to a concentration
of a compound) as seen in Figure 1A. The decision bound-
ary is evaluated for generalizability by classifying withheld
data, referred to as a test set. As a result, an SVM accuracy
metric is calculated to reflect the machine’s ability to iden-
tify a cardioactive effect (e.g., 75% accuracymeans that out
of 100 data points, the machine could correctly classify 75
of them). To account for variations within the dataset, mul-
tiple runs are performed to calculate the mean SVM accu-
racy. A value of approximately 50% mean SVM accuracy
suggests non-cardioactivity as the machine cannot distin-
guish between treated hvCTS data from control data, and
the classification becomes random. Prominent cardioactive
effects allow the space between the data from treated and
control conditions to become more distinguishable, lead-
ing to a higher SVM accuracy with 100% being the
maximum.
The second step was the utilization of multiclass SVM to
create and evaluate amodel. The 11 compounds (excluding
aspirin) were divided into two groups (Figure 1B). The first
group was referred to as a ‘‘drug library’’ and used to trainStem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017 1561
Table 1. Library Compounds
Compound Name Class Description Test Range (M)
Number of
hvCTS (n)
Nifedipine Ca2+ channel blocker an L-type Ca2+ channel blocker known to
shorten action potential duration (Harris
et al., 2013)
108 to 3.0 3 105 10
Mibefradil Ca2+ channel blocker a tetralol derivative that blocks both L- and
T-type Ca2+ channels with higher affinity for
T-type (Martin et al., 2000)
109 to 3.0 3 106 6
Isoproterenol adrenergic agonist a mixed b-adrenergic agonists; compound
is non-selective in terms of breceptors
(Steinberg, 1999)
108 to 104 10
Norepinephrine adrenergic agonist mixed adrenergic agonist that stimulates
both a and breceptors (Yang et al., 2014)
109 to 105 8
Digoxin cardiac glycoside a cardiac glycoside that inhibits Na+/K+-ATPase,
resulting in higher intracellular Na+; higher
Na+ concentration suppresses the Na+/Ca2+
exchanger causing the accumulation of
intracellular Ca2+ (Katz et al., 2010)
108 to 104 9
Ouabain cardiac glycoside a cardiac glycoside that affects Na+/K+-ATPase,
which consists of both a and b subunits; has a
lower affinity for a subunits than digoxin (Katz
et al., 2010).
108 to 104 10
Flecainide hERG K+ channel blocker a mixed hERG K+ blocker that also inhibits
Na+ channels, causing effects on action
potential repolarization and conduction
(Harris et al., 2013)
108 to 104 8
E-4031 hERG K+ channel blocker a pure hERG K+ channel blocker known for its
pro-arrhythmic potential (Ziupa et al., 2014)
108 to 104 8
Cisapride hERG K+ channel blocker a serotonin (5-HT4) receptor agonist that also
inhibits the hERG K+ channel (Wong et al., 2010)
108 to 104 9
Lisinopril ACE inhibitor an ACE inhibitor, which reduces vasoconstriction
and lowers blood pressure in patients (Williams,
1988)
108 to 104 8
Ramipril ACE inhibitor an ACE inhibitor; it does not block ACE until it
is converted by the liver (Williams, 1988)
109 to 105 7
Aspirin non-cardioactive
reference
non-steroidal anti-inflammatory drug that has
been shown to have no cardioactive effects in
screening platforms (Maddah et al., 2015)
108 to 104 6
n refers to independent biological replicates. hvCTS, human ventricular cardiac tissue strips; hERG, human ether-a-go-go-related gene; ACE, angiotensin-
converting enzyme.amodel that defined the boundaries of each drug class. The
second group was completely withheld from the computer
throughout the entire training and tuningof themodel and
was referred to as the ‘‘unknown’’ compounds. To
normalize for the varying degrees of cardioactivity among
compounds, the concentration of a compound that
achieved a metric closest to 85% mean SVM accuracy (see
Supplemental Experimental Procedures) was used in the
formation and evaluation of the model. To ensure that the1562 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017library was generalizable or had the capability to classify it-
self, a subset of thefirst group’s data, a test set,was randomly
withheld from the computer prior to training. The library
was evaluated on its performance to accurately identify
this test set. Afterward, the library was asked to predict the
unknown compounds, and its performance was evaluated
for predictive capabilities. To account for the variation
and random selection of training and test sets, the creation
and evaluation of the models were performed 50 times.
Figure 1. Determining Cardioactivity and
Predicting Mechanistic Action
(A) To determine if a concentration of a
compound was cardioactive, parameters
describing the force waveforms were
compared with those of vehicle study with
the binary SVM approach. If the compound
does not modulate the contractile behavior
of hvCTSs, the generated data points would
be similar to those of vehicle, yielding poor
separation and an SVM accuracy of approx-
imately 50%. However, if a compound’s
cardioactive effects become more distin-
guishable, separation between the two
groups becomes more feasible and results in
a higher SVM accuracy (100% as maximum
distinguishability). This binary SVM
approach generates a singular quantitative
index that describes the degree of car-
dioactivity of a given concentration for a
drug compound.
(B) To create a model for the prediction of
mechanistic action, data from screened
compounds were divided into two groups:
library and unknown. Using data from the
library group, the machine defined bound-
aries that represent various drug families.
The model was evaluated for its predictive
capabilities by having the machine classify
the unknown compounds.Control Experiments
Although the hvCTSs (Figure 2A) were examined under
temperature-controlled conditions, there was an observ-
able drift in contractile behavior of the vehicle-treated
hvCTSs. For example, the relative measured maximum
developed force increased for all pacing frequencies by a
cumulative average of 16.96% ± 0.83% upon the ninth
serial addition (Figure 2B). To account and normalize
for baseline drift, each drug condition was compared
with its respective vehicle condition via binary SVM
(e.g., measurements of the seventh serial drug addition
were compared with those of vehicle-treated hvCTSs at
the seventh serial addition). To establish a benchmark
of non-cardioactivity, a subset of the vehicle-treated
hvCTSs was randomly selected to model a non-cardioac-
tive compound. Binary SVM was then performedbetween the subset and a corresponding control group
of equal size (n).
To ensure that the number of hvCTSs in the subset had
no effect, the calculations were performed with the sample
size, n, equal to 6–10, whichmatched the range of numbers
of strips used in each drug study of the 12 tested com-
pounds. As expected, the SVM accuracy, regardless of the
size of n, was approximately 50% for all serial additions
(Figure 2C). These results indicated that there were no
consistent and distinguishable trends within each serial
addition, and therefore a reference of non-cardioactivity
was created.
To validate this reference of non-cardioactivity, drug
screens of aspirin from the database were used as negative
controls. Aspirin is known to have no cardioactive effects
on hPSC-CMs (Lu et al., 2015; Maddah et al., 2015; ScottStem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017 1563
Figure 2. Control Experiments and Screen of Non-cardioactive Compounds
(A) hvCTSs were formed by compaction of hPSC-CMS, fibroblasts, and extracellular matrix solution around two PDMS posts. Force was
derived from the deflection of the posts. Scale bar, 10 mm.
(B) hvCTSs of the vehicle study exhibited a drift in contractile behavior after serial additions of water (n = 28).
(C) To normalize for shift, data from each drug condition were compared with its respective vehicle condition (matching serial addition
number). With this, a benchmark of non-cardioactivity was created with subsets of vehicle-treated strips being modeled as strips exposed
to non-cardioactive compounds and compared with other vehicle-treated strips with binary SVM. The number of tissue strips in the subset
(n = 6–10) had no effect as SVM accuracies were approximately 50% for all conditions.
(D) To assess the non-cardioactivity benchmark, the data of aspirin-treated hvCTSs indicated no statistical difference from the vehicle
study over the tested range (n = 6). n refers to independent biological replicates.
All results are presented as means ± SD.et al., 2014). The SVM accuracies of the aspirin drug screens
(n = 6) had an average of 52.85% ± 1.77% among all serial
additions (10 nM to 100 mM). None of the conditions were
statistically different from vehicle counterparts, indicating
non-cardioactivity by aspirin (Figure 2D).
Generalizability of the Drug Classification Model
In setting up the drug classification model, the 11 non-
reference compounds were compared with vehicle-treated
tissue strips with the aforementioned binary SVM
approach. At one or more of the tested concentrations,
all but two compounds, lisinopril and ramipril, had
SVM accuracies that were significantly greater than those
of the respective vehicle studies (Figure 3). The ACE inhib-
itors, lisinopril and ramipril, did not have detectable car-
dioactive effects on hvCTS contractility, consistent with
the results of other platforms (Harmer et al., 2012; Scott
et al., 2014). Therefore, the ACE inhibitor class was
removed from the library resulting in a four-class system.
Mibefradil, norepinephrine, ouabain, and cisapride were1564 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017chosen to represent the unknown compound group on
which the model would make de novo predictions. Mibe-
fradil and cisapride were of particular interest because
both compounds had received market approval and
were subsequently withdrawn (Li et al., 2016). Nifedipine,
isoproterenol, and digoxin were chosen to represent the
Ca2+ channel blocker, adrenergic agonist, and cardiac
glycoside classes, respectively. As both flecainide and
E-4031 have known hERG K+ channel-blocking capabil-
ities, the impact of having either compound represent
the hERG K+ blocker family was evaluated by generating
the multiclass model under three different conditions:
(1) flecainide only, (2) E-4031 only, and (3) both flecainide
and E-4031.
A subset of the data was always withheld from the ma-
chine prior to training in each of the runs. This withheld
set quantified the generalizability in the models and
ensured that overfitting had not occurred. Upon asking
the machine to classify these test sets, the multiclass
models demonstrated good generalizability by being able
Figure 3. Applying Cardioactive Index to Drug Responses
Implementation of binary SVM to determine cardioactive effects of 11 compounds, including: (A) nifedipine (p % 0.0063; n = 10),
(B) mibefradil (p% 0.0063; n = 6), (C) isoproterenol (p% 0.0055; n = 10), (D) norepinephrine (p% 0.0055; n = 8), (E) digoxin (p%
0.0055; n = 9), (F) ouabain (p% 0.0055; n = 10), (G) flecainide (p% 0.0055; n = 8), (H) E-4031 (p% 0.0071; n = 8), (I) cisapride (p%
0.0055; n = 9), (J) lisinopril (p% 0.0055; n = 8), and (K) ramipril (p% 0.0055; n = 7). Red circles indicate statistical significance in
comparison with vehicle-treated hvCTSs. p values are adjusted with a Bonferroni correction. n refers to independent biological replicates.
All results are presented as means ± SD.to correctly classify itself at an average accuracy rate of
76.09% ± 6.43%, 78.29% ± 5.34%, and 73.61% ± 5.19%
for the flecainide only, E-4031 only, and flecainide and
E-4031 conditions, respectively (Figure 4).
In all three conditions, the multiclass models behaved
similarly in that both the nifedipine and isoproterenol clas-
sifiers performed the best by always achieving the highest
F1 score values, a metric that ranges from 0 to 1 with 1 rep-resenting perfection in the model’s classification. This
performance indicates that the data points of the nifedi-
pine and isoproterenol compounds occupied very distinct
boundaries compared with the other two classes, allowing
for the binary learners to more accurately separate these
compounds from others. For perspective on the quality of
model performance, if there were no discernable differ-
ences among the four compounds for the machine to use,Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017 1565
Figure 4. Generalizability of Drug Classifi-
cation Models with Varying Representative
Compound(s) for the hERG K+ Channel
Blocker Family
(A) Condition 1: flecainide. Generalizability
was evaluated by having the model classify a
withheld test set composed of compounds
used to define the library. (Left) The confu-
sion matrix displays the average number of
classified contractile events (individual
twitches in acquired waveform) over 50 runs
and is imposed with a color scale that in-
dicates precision rate. (Right) Summary of
the metrics evaluating performance. F1 scores
are above 0.6 for all classifiers, indicating
good predictability.
(B) Condition 2: E-4031. (Left) Confusion
matrix indicates that all compounds were
being correctly classified as themselves as the
diagonal of the matrix had the highest pre-
cision rate. (Right) Metrics indicate a similar
performance between conditions 1 and 2.
(C) Condition 3: flecainide and E-4031. (Left)
Confusion matrix indicates no major effect on
generalizability by having two compounds
define a class. (Right) Similar to conditions
1 and 2, F1 scores are all above 0.6, indicating
good generalizability of the model.
All results are presented as means ± SD.the expected values for precision (i.e., positive predictive
value), recall (i.e., sensitivity), and accuracy would be a
rate of 25% with an F1 score of 0.25 (see Experimental Pro-
cedures). As all three multiclass models demonstrated good
generalizability with average accuracy rates exceeding
70%, these results suggest the setup of the model was
robust to the choice of compound representing the hERG
K+ channel blocker family.
Prediction on Unknown Compounds
With each condition’s model established and evaluated,
the machine was then asked to predict the data from the
unknown compounds group. In the first scenario with
flecainide as the only hERG K+ channel blocker representa-
tive, the multiclass model was able to correctly assign the
four unknown compounds to their corresponding counter-
parts with an average accuracy of 71.69% ± 1.96% (Fig-
ure 5A). The four binary classifiers of this model demon-1566 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017strated overall predictability by all having an average F1
score above 0.6.
When the second drug classmodel (only E-4031 defining
the hERG K+ channel blocker class) was used to predict the
unknown compounds, the average accuracy diminished to
65.37% ± 2.33% (Figure 5B). This decrease was mainly the
result of the contractile events from hvCTSs exposed to cis-
apride being miscategorized. Of the 779 contractile events
from hvCTSs exposed to cisapride, on average, 46.76% ±
7.00% of the events were incorrectly labeled as hvCTSs
affected by a cardiac glycoside. These misclassifications
yielded a poor precision rate, 20.51% ± 11.20%, and subse-
quently, a low F1 score, 0.27 ± 0.11, for the hERG K
+ chan-
nel blocker classifier. As for the classifiers of the other three
families, they performed comparably with those of the first
condition, and all had an average F1 score over 0.6. These
results indicate that using only data of hvCTSs exposed to
E-4031 is not sufficient for defining the hERG K+ channel
Figure 5. Predictability of Drug Classifica-
tion Libraries with Varying Representative
Compound(s) for the hERG K+ Channel
Blocker Family
(A) Condition 1: flecainide. Libraries of all
three conditions were evaluated for capabil-
ities to predict drug families of compounds
previously unseen by the machine. (Left)
Confusion matrix displays the average num-
ber of predicted contractile events (individ-
ual twitches in acquired waveform) from the
unknown group over 50 runs. Unknown
compounds were classified to the correct
drug family as the precision rate was highest
along the diagonal of the matrix. (Right) The
model demonstrated good predictability as
the macro-average of the F1 score was 0.71.
(B) Condition 2: E-4031. (Left) Cisapride was
predominantly mislabeled as a member of the
cardiac glycoside family, represented by
digoxin. The other three compounds were
classified correctly to their respective drug
families. (Right) The classifier of the hERG K+
channel blocker class had an F1 score of 0.27.
As the other three classifiers maintained an
F1 score above 0.6, E-4031 did not define
boundaries similar to that of cisapride.
(C) Condition 3: flecainide and E-4031. (Left)
Precision rates are highest along the diago-
nal of the matrix. (Right) The model yielded
good predictability and was not affected by
the inclusion of E-4031 data to those of fle-
cainide.
All results are presented as means ± SD.blocker family within amulticlass model and enabling that
model to correctly predict cisapride’s mechanistic action
on cardiac tissue contractility.
In the last conditionwhere themachinewas trainedwith
both flecainide and E-4031 representing the hERGK+ chan-
nel blocker family, the average accuracy was 71.43% ±
2.09% (Figure 5C). All four classifiers had an average F1
score higher than 0.6. Unlike the second condition, the
hERG K+ channel blocker classifier had a precision rate
higher than 25% at 66.87% ± 8.05%. Similar to that of
the first condition, the macro-average of the F1 scores for
this multiclass model was 0.71, demonstrating good pre-
dictability. These results suggest that the data points from
the hvCTSs exposed to flecainide designated boundaries
within the model that were similar to those of cisapride-
treated hvCTSs. Finally, the inclusion of E-4031 data with
the flecainide data did not negatively affect the multiclassmodel’s ability to correctly predict cisapride’s mechanistic
action as neither the precision rate nor the recall rate fell
below 41% as they did in the second condition.
Class Relationship Metrics
Once the drug classes were predicted, the concentrations of
library compounds that induced the most similar cardioac-
tive effects as the unknown compounds were computed
(Figure S2; protocol in Supplemental Experimental Proced-
ures). These relationship metrics are summarized in Table
S1. For example, an estimated 5.35 3 105 M digoxin
would be needed to evoke a level of cardioactivity that
matches ouabain tested at 1.03 105M. Such relationships
could provide insights about drug potency. In the afore-
mentioned example, ouabain would be considered the
more potent compound as it requires approximately
5-fold lower concentration to achieve the same level ofStem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017 1567
cardioactivity. Ouabain’s higher potency has been
observed in other in vitro studies (Guo et al., 2011; Katz
et al., 2010).
Decoupling Force-Frequency Relationship
While the concept of examining multiple parameters from
waveforms has been pursued lately, some studies have sug-
gested that only a few select parameters (e.g., peak count)
are necessary in assessing a compound’s cardioactivity as
other parameters provide no further mechanistic insight
(Lu et al., 2015; Pointon et al., 2016; Sirenko et al., 2013).
This is primarily true when the hPSC-CMs are spontane-
ously beating, meaning the force generated is linked to
beating frequency. This study’s dataset affirmed the impor-
tance of decoupling this force-frequency relationship
through the pacing of the tissues. By setting a fixed pacing
frequency, any changes to the force waveform can be truly
accredited to a compound’s inotropic and lusitropic effects.
For example, if the nifedipine-treated strips were allowed to
spontaneously beat, a positive chronotropic effect would
have most likely been observed (Guo et al., 2011; Harris
et al., 2013; Pillekamp et al., 2012). As the hvCTSs dis-
played anegative force-frequency relationship (Figure S3A),
a decrease in maximum developed force could not be
directly linked to either chronotropic or inotropic effects.
When 0.3 mM nifedipine-treated hvCTSs were paced at
1 Hz, the captured frequency of the tissue was 0.99 ±
0.01 Hz and the maximum developed force decreased by
45.69% ± 10.42% (Figure S3B). This paced data confidently
confirmed nifedipine had a negative inotropic effect.
Examination of Cardioactive Effects
The data were further examined on an individual param-
eter basis to better comprehend and confirm the perfor-
mance of the multiclass models and their ability to differ-
entiate between different mechanistic actions (Figure S4).
The adrenergic agonists and cardiac glycosides were
expected to induce a positive inotropic response in the
hvCTSs, while the Ca2+ and hERG K+ channel blockers
would induce a negative inotropic response. The negative
inotropic agents prompted distinct decreases in the
maximum force generated among hvCTSs; however, the
hvCTS sensitivity to positive inotropic agents was not
very apparent. For example, hvCTSs exposed to 10 mM
isoproterenol and paced at 0.5 Hz had a similar increase
in maximum developed force to that of respective
vehicle-treated strips (10.42% ± 16.23% and 15.76% ±
21.05%, respectively), suggesting the compoundhad negli-
gible inotropic effects (Figures S5A and S5B) (Turnbull et al.,
2014). Rather, isoproterenol’s cardioactive effects mani-
fested in other parameters. For example, the duration of
the relaxation phase or time from maximum developed
force to 95% cutoff decreased by 22.19% ± 19.35% for1568 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017the strips exposed to 10 mM isoproterenol, while those of
the vehicle-treated strips experienced essentially no
change. Thus, through the various parameters, machine
learning was able to leverage the positive lusitropic effects
in both binary and multiclass SVM to distinguish the
adrenergic agonist class.
Cardiac glycoside-treated hvCTSs also demonstrated the
system’s sensitivity to positive inotropes. Typically, these
compounds increase the Ca2+ transient amplitude and
amplitude of contractility transients; however, in this
dataset, the hvCTSs decreased in maximum developed
force as the concentration increased (Figure S5C) (Demp-
sey et al., 2016; Ravenscroft et al., 2016). Such results
could be attributed to cardiac glycoside toxicity or imma-
ture phenotype. Studies have shown that above 3 mM
digoxin or ouabain, monolayers of hPSC-CMs stopped
beating (Dempsey et al., 2016; Guo et al., 2013; Sirenko
et al., 2013). In this dataset, the highest concentration
applied for both cardiac glycosides was 100 mM. At
100 mM ouabain, 4 of the 10 treated strips stopped beating
at all pacing frequencies.
Like those of isoproterenol, cardioactive effects of the car-
diac glycosides at lower concentrations appeared in other
parameters. When either the concentration of cisapride
or digoxin increased, the maximum developed force
decreased while the duration of the relaxation phase
increased (Figures S5C and S5D). If limited to observation
of only these two parameters, one might conclude that cis-
apride and digoxin are related. But upon visual inspection
of the force traces, it is evident that the compounds have
distinct effects on hvCTSs andmechanistic actions (Figures
S3E and S3F). Changes in these parameters were clearly
unique to the cardiac glycoside family as the ouabain-
treated strips were correctly predicted from the other three
classes.DISCUSSION
In recognition of the need for better detection of drug-
induced cardiotoxicity, numerous methodologies have
emerged to capture and quantify the attributes of hPSC-
CMs when exposed to cardioactive compounds, ranging
from calcium transients to contractile force. The nature of
the output data becomes multidimensional when multiple
experimental conditions are present or a multiplex system
is used (Dempsey et al., 2016). In this study, we present the
use of supervised machine learning to exploit multidimen-
sional data and provide relevant information in an auto-
matedmanner. Besides indicating if a compoundwas cardi-
oactive, the machine constructed a multiclass drug model
that accurately classified cardioactive compounds that it
had never previously encountered. This comprehensive
approach can be readily applied to other screening plat-
forms to more fully utilize generated datasets and enhance
evidence-based decision-making for drug development.
With multiclass SVM, drug classification libraries were
established under various conditions to examine the effects
on predictive performance. The conditions that yielded the
best performance in predicting mechanistic action were
the two libraries that included flecainide as a representative
of the hERG K+ channel blocker family. In both libraries,
the macro-averages of F1 scores were 0.71 (the macro-
average of F1 scores would be 0.25 if random classifiers
were used).While this clear difference in F1 scores indicates
that the models have the capability to predict a com-
pound’s mechanistic action, there are opportunities to
further improve model performance and obtain F1 scores
closer to 1, indicating reduction in errors.
One method to improve model performance is to define
each drug family with multiple compounds. By having
only one compound define a class, there is a risk of only
defining a partial region of space that the drug class truly
encompasses. The data of E-4031 exemplified this when
it was tasked with defining the hERG K+ channel blocker
family. E-4031’s defined boundaries did not match or
include those of cisapride, another hERG K+ channel
blocker, causing classification of cisapride to be closer to
that of the cardiac glycoside family. The inclusion of flecai-
nide, a mixed hERG K+ channel blocker, with E-4031 in the
definition of the class allowed for the correct prediction of
cisapride without adversely affecting the predictive capa-
bility of the remaining classes. Although the addition of
E-4031 to the hERG K+ channel blocker definition does
not necessarily improve the predictive capability with
respect to cisapride classification, establishing a more
expansive region of space to define the hERG K+ channel
blocker class may improve prediction of other unknown
hERG K+ channel blockers that have effects more similar
to E-4031 than flecainide. These results also suggest the
potential of having subgroups within classes of the model,
which can be achieved through a series of multiclass classi-
fications. For instance, a compound can be predicted as a
Ca2+ channel blocker in the first classification; within this
family, the compound can be subsequently categorized
into a subgroup (e.g., defined by frequency-dependent car-
dioactivity). As machine learning does not define drug
classes with a priori knowledge (e.g., guidelines on how pa-
rameters are expected to change), the number of drug fam-
ilies and subclasses that can be defined within a model are
not limited. The unbiased and automated nature of
machine learning is also advantageous when a new drug
family needs to be added, because no rubric needs to be
manually amended and re-evaluated.
This study demonstrates the potential of machine
learning for providing insights in the detection of cardioac-tivity using hPSC-CMs. The basis of this study’s libraries
was an error-correcting output codes approach with binary
learners being SVM. Different binary learners, such as deci-
sion trees, should be explored alongside completely
different approaches (e.g., neural networks). The ideal ma-
chine learning technique should balance predictive capa-
bilities and use of computational resources. In this study,
all models were generated with a standard desktop. Each
calculated instance of a model took approximately 4 hr.
However, once all models were formed, the predictions
made on unknown compounds were on the timescale of
seconds.
Improvements of the multiclass drug libraries can also be
achieved from enhancements of the hvCTSs and acquisi-
tion system. In particular, the sensitivity of this system to
positive inotropic compounds can be increased by address-
ing two issues: the maturity of stem cell-derived cardio-
myocytes and the drifting baseline of vehicle-treated strips.
Studies have shown that hPSC-CMs elicit a minimal to
non-existent response to certain positive inotropic com-
pounds, such as b-adrenergic agonists, because of imma-
ture intracellular structures (Lundy et al., 2013; Pillekamp
et al., 2012). When these diminished responses are paired
with a baseline that has increasing contractility over
time, positive inotropic effects of a compound can get
masked and become harder to detect as seen in the afore-
mentioned isoproterenol drug screen. While hvCTSs were
arranged in an aligned manner and co-cultured with fibro-
blasts, they can be further matured through additional
techniques, such as conditioning by electrical stimulation,
a cellular tri-culture including endothelial cells, or forced
expression of selected proteins (Eng et al., 2016; Liu et al.,
2009; Ravenscroft et al., 2016). As for stabilization of the
baseline, different components of the setup, ranging from
pH to CO2 levels in an ambient environment, should be
re-evaluated to minimize overall drift during serial addi-
tions. Increasing the system’s sensitivity to positive
inotropic agents would yield even more distinct bound-
aries and subsequently better predictability in the drug
classification libraries.
While we demonstrated the importance of pacing
hvCTSs, a limitation of this study is the absence of
responses of spontaneously beating hvCTSs to cardioac-
tive compounds. These data would provide understanding
of a compound’s chronotropic effects. Even though the
model has already demonstrated good predictability on
inotropic- and lusitropic-related data alone, the model
would benefit from chronotropic-related data as it would
provide more dimensions in which compounds can
further distinguish themselves and yield better
predictability.
In summary, we present the implementation of super-
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hvCTSs exposed to drugs while paced at various fre-
quencies. In an automated fashion, this machine learning
approach is able to not only determine if a compound is
cardioactive but it can predict themechanistic action along
with other metrics. Furthermore, this approach can be
adapted to state-of-the-art tissue-engineered cardiac
models, including different forms of signals (e.g., calcium
transients, micro-electrode array, and optical recordings),
and has the potential to integrate diverse output data of
multiplex systems or even those across platforms. Along
with analyses of compounds with acute cardioactive
effects, machine learning can be readily applied with
non-invasive techniques to longitudinal studies to inspect
a compound’s chronic effects. Moreover, in the future,
machine learning may be utilized on a grander scale by
incorporating past clinical data to determine the optimal
combination of in vitro and in silico data for the prediction
of drug-induced cardiotoxicity in patients.EXPERIMENTAL PROCEDURES
hvCTS Formation
Human ventricular cardiomyocytes were differentiated from an
hES2 stem cell line with a Wnt inhibitor-based protocol as
described previously (Weng et al., 2014). Human ventricular car-
diac tissue strips (hvCTS) were then formed by mixing cardiomyo-
cytes (100,000 cells per strip) at 14–16 days post differentiation
with a solution of bovine collagen I (2 mg/mL), Matrigel
(0.9 mg/mL), and human foreskin fibroblasts (100,000 cells per
strip) as previously described (Turnbull et al., 2014). The cell-ma-
trix solution (100 mL per tissue strip) was injected into a custom
polydimethylsiloxane (PDMS) force-sensing bioreactor device
and placed in an incubator (37C and 5% CO2). Formed hvCTSs
were fed DMEM with 10% newborn calf serum, 1% penicillin-
streptomycin, and 0.1% amphotericin B. The PDMS device con-
tains two flexible vertical end posts to which the tissue anchors,
causing the posts to deflect as the tissue beats. Contractile force
measurements were captured with a high-speed (100 fps) CCD
camera while custom LabVIEW software tracked the centroid
movement of the flexible post tips. Force was converted from the
deflection of the PDMS posts by an elastic beam-bending equation
(Serrao et al., 2012). A customMATLAB script was used to calculate
17 parameters that described the overall shape of the force traces
for each contractile event (Figure S1). Each contraction was re-
garded as an individual data point for the machine learning
analysis.Drug Treatment
Seven to eight days post tissue formation, hvCTS were exposed
to drugs for pharmacodynamic analysis. Flecainide, lisinopril,
norepinephrine, and ramipril were provided by Pfizer, while all
other compounds were purchased form Sigma-Aldrich. Com-
pounds were initially resuspended in DMSO and subsequently
diluted in water for final concentrations of less than 0.1%
(vol/vol) DMSO. The PDMS device containing the hvCTS was1570 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017placed onto a heated stage (37C) under a dissecting microscope.
Before either vehicle or drug addition, the medium was replaced
with DMEM containing high glucose (4.5 g/L) and HEPES
without phenol red. Drug doses were added to a tissue in
a consecutively increasing manner up to 10 concentrations
with 3 min between measurements. Vehicle doses containing
only water were applied similarly. A pulse stimulator (AMPI
Master-9) connected to platinum wires electrically paced the
hvCTSs with a monophasic electric field of 5 V/cm and a
10 ms pulse duration.Machine Learning
To establish the drug class model, we identified individual com-
pounds that respectively represented our defined classes. The
compounds and the corresponding tested concentrations are
listed in Table 1. To determine which concentration of a chosen
compound to add to the model, we first gauged each compound’s
level of cardioactivity by utilizing binary SVM (Figure S6) (Lee
et al., 2015). To normalize for the increasing variation seen in
hvCTS contractile behavior during the later serial additions of
the vehicle studies, the SVM was performed between each con-
centration of a compound and the vehicle data from the corre-
sponding serial addition number in which the concentration
was achieved (Figure 1A). Specific details and rationale regarding
the optimization of SVM classifiers and other implemented ma-
chine learning approaches are in the Supplemental Experimental
Procedures.
For multiclass classification, we then selected the compound
concentration that met two criteria: (1) a binary SVM accuracy
closest to 85% and (2) at least six of all screened tissue strips
were still responsive to electrical stimulation (see Supplemental
Experimental Procedures). As seen in Figure 1B, we then divided
the compounds into two groups: one used to train the multiclass
model and one to represent unknown compounds for predic-
tions. During this separation, it was ensured that each class was
at least represented by one compound within the two groups.
For training of the model, we used an error-correcting output co-
des approach with the binary learners being SVM (Dietterich,
1995). To confirm generalizability of the generated models, we
randomly pre-allocated a third of the data as a test set prior to
the training. Finally, we evaluated the multiclass model with
this test set and then asked the machine to predict the classes
of the contractile beats derived from the unknown compounds
group.Statistics
SVM accuracies of strips exposed to a drug condition were
compared with those of the non-cardioactive benchmark by using
Student’s t test (desired a value of 0.05) with a Bonferroni correc-
tion (m, number of tests or hypotheses, was dependent on the
number of drug additions in a screen). If the adjusted p value
was statistically significant, the drug condition was considered to
have incited irregular behavior in hvCTSs and was labeled as cardi-
oactive. The Bonferroni correction was also applied when exam-
ining changes in specific parameters.
To analyze the performance of the multiclass models, confu-
sion matrices were generated for each of the 50 runs. In a
confusion matrix, M, the precision and recall rates were defined
as follows:
Precisioni =
MiiPn
j=1Mij
; Recallj =
MiiPn
i=1Mij
:
The precision and recall rates were calculated for each of the classi-
fiers. To further summarize thesemetrics, the F1 score, theharmonic
mean of precision and recall, was computed and defined as follows:
F1 scorei =
23 Precisioni3Recalli
Precisioni +Recalli
:
A model that is perfect would achieve an F1 score of 1. If a model
were composed of s number of classes and had random classifiers,
the expected F1score would be 1=s. To assess the model as a whole,
accuracy, defined as
Accuracymodel =
Pn
i=1MiiPn
i=1
Pn
j=1Mij
:
was calculated. In summarizing the 50 runs of each model, all
calculated metrics were averaged and a confusion matrix contain-
ing the average number of contractile events over all runs was
provided. Contractile events were defined as the individual
twitches in the force readouts acquired from the tissue strips. All re-
ported sample sizes (n) refer to independent tissue strips (biological
replicates). All descriptive statistics are in the format of mean ± SD.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, six figures, one table, and one data file and can be
found with this article online at https://doi.org/10.1016/j.stemcr.
2017.09.008.
AUTHOR CONTRIBUTIONS
E.K.L. and D.D.T. initiated and conceived project. G.W., C.W.C.,
K.D.C., R.A.L., and M.K. supervised the project. W.K. and P.C.
collected biological data. E.K.L. implemented the machine
learning concepts. E.K.L., D.D.T., W.K., K.D.C., and M.K. analyzed
data. E.K.L. and D.D.T. wrote the manuscript. W.K., K.D.C., R.A.L.,
and M.K. contributed to the writing of the manuscript.
ACKNOWLEDGMENTS
Funding for this research was in part by Novoheart LTD. R.L.,
K.D.C., and M.K. have equity interest in Novoheart Ltd, a com-
pany thatmay potentially benefit from the research results. During
the period between initial manuscript submission and acceptance,
E.K.L. has become an employee at Novoheart Ltd. D.D.T., G.W.,
and C.W.C. are employees of Novoheart Ltd. The terms of this
arrangement have been reviewed and approved by the University
of California in accordance with its conflict of interest policies.
This work was also supported by the Innovation Technology
Fund, HKSAR (ITS/131/13FX). We would like to thank Dr. Bernard
Fermini for providing the compounds with known inotropic
classification.Received: June 1, 2017
Revised: September 11, 2017
Accepted: September 12, 2017
Published: October 12, 2017REFERENCES
Chen, A., Lee, E., Tu, R., Santiago, K., Grosberg, A., Fowlkes, C., and
Khine,M. (2014). Integrated platform for functionalmonitoring of
biomimetic heart sheets derived from human pluripotent stem
cells. Biomaterials 35, 675–683.
Dempsey, G.T., Chaudhary, K.W., Atwater, N., Nguyen, C., Brown,
B.S., McNeish, J.D., Cohen, A.E., and Kralj, J.M. (2016). Cardiotox-
icity screening with simultaneous optogenetic pacing, voltage
imaging and calcium imaging. J. Pharmacol. Toxicol. Methods
81, 240–250.
Dick, E., Rajamohan, D., Ronksley, J., and Denning, C. (2010).
Evaluating the utility of cardiomyocytes from human pluripotent
stem cells for drug screening. Biochem. Soc. Trans. 38, 1037–1045.
Dietterich, T.G. (1995). Solving multiclass learning problems via
error-correcting output codes. J. Artif. Intell. Res. 2, 263–286.
Eng, G., Lee, B.W., Protas, L., Gagliardi, M., Brown, K., Kass, R.S.,
Keller, G., Robinson, R.B., and Vunjak-novakovic, G. (2016).
Autonomous beating rate adaptation in human stem cell-derived
cardiomyocytes. Nat. Commun. 7, 1–10.
FDA. (2005). Guidance for Industry: S7B Nonclinical Evaluation of
by Human Pharmaceuticals Guidance for Industry (U.S. Depart-
ment of Health and Human Services, Food and Drug Administra-
tion, Center for Drug Evaluation and Research (CDER), Center for
Biologics Evaluation and Research (CBER)). https://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm074963.pdf.
FDA (2016). Zelnorm (tegaserod maleate) Information. https://
www.fda.gov/Drugs/DrugSafety/ucm103223.htm.
Ferriman, A. (2000). UK licence for cisapride suspended cancer
drug may cause heart failure. Br. Med. J. 321, 2000.
Guo, L., Qian, J., Abrams, R., Tang, H.,Weiser, T., Sanders,M.J., and
Kolaja, K.L. (2011). The electrophysiological effects of cardiac gly-
cosides in cardiomyocytes and in guinea pig isolated hearts. Cell.
Physiol. Biochem. 27, 453–462.
Guo, L., Coyle, L., Abrams, R.M.C., Kemper, R., Chiao, E.T., and Ko-
laja, K.L. (2013). Refining the human iPSC-cardiomyocyte
arrhythmic risk assessment model. Toxicol. Sci. 136, 581–594.
Harmer, A.R., Abi-Gerges, N., Morton, M.J., Pullen, G.F., Valentin,
J.P., and Pollard, C.E. (2012). Validation of an in vitro contractility
assay using canine ventricular myocytes. Toxicol. Appl. Pharma-
col. 260, 162–172.
Harris, G., and Koli, E. (2005). Lucrative Drug, Danger Signals and
the F.D.A (New York Times), pp. 1–9.
Harris, K., Aylott, M., Cui, Y., Louttit, J.B., McMahon, N.C., and
Sridhar, A. (2013). Comparison of electrophysiological data from
human-induced pluripotent stem cell-derived cardiomyocytes to
functional preclinical safety assays. Toxicol. Sci. 134, 412–426.
Huebsch, N., Loskill, P., Deveshwar, N., Spencer, C.I., Judge, L.M.,
Mandegar, M.A., Fox, C.B., Mohamed, T.M.A., Ma, Z., Mathur, A.,Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017 1571
et al. (2016). Miniaturized iPS-cell-derived cardiac muscles for
physiologically relevant drug response analyses. Sci. Rep. 6, 24726.
Katz, A., Lifshitz, Y., Bab-Dinitz, E., Kapri-Pardes, E., Goldshleger,
R., Tal, D.M., and Karlish, S.J.D. (2010). Selectivity of digitalis gly-
cosides for isoforms of human Na,K-ATPase. J. Biol. Chem. 285,
19582–19592.
Lee, E.J., Kim, D.E., Azeloglu, E.U., and Costa, K.D. (2008). Engi-
neered cardiac organoid chambers: toward a functional biological
model ventricle. Tissue Eng. Part A 14, 215–225.
Lee, E.K., Kurokawa, Y.K., Tu, R., George, S.C., and Khine, M.
(2015). Machine learning plus optical flow: a simple and sensitive
method to detect cardioactive drugs. Sci. Rep. 5, 11817.
Li, X., Zhang, R., Zhao, B., Lossin, C., and Cao, Z. (2016). Cardio-
toxicity screening: a review of rapid-throughput in vitro
approaches. Arch. Toxicol. 90, 1803–1816.
Liu, J., Lieu, D.K., Siu, C.W., Fu, J.D., Tse, H.F., and Li, R.A. (2009).
Facilitated maturation of Ca 2 + handling properties of human
embryonic stem cell-derived cardiomyocytes by calsequestrin
expression. Am. J. Physiol. Cell Physiol. 297, 152–159.
Lu, H.R.,Whittaker, R., Price, J.H., Vega, R., Pfeiffer, E.R., Cerignoli,
F., Towart, R., and Gallacher, D.J. (2015). High throughput mea-
surement of Ca++ dynamics in human stem cell-derived cardio-
myocytes by kinetic image cytometery: a cardiac risk assessment
characterization using a large panel of cardioactive and inactive
compounds. Toxicol. Sci. 148, 503–516.
Lundy, S.D., Zhu, W.-Z., Regnier, M., and Laflamme, M.A. (2013).
Structural and functional maturation of cardiomyocytes derived
fromhumanpluripotent stemcells. StemCellsDev.22, 1991–2002.
Maddah, M., Heidmann, J.D., Mandegar, M.A., Walker, C.D., Bo-
louki, S., Conklin, B.R., and Loewke, K.E. (2015). A non-invasive
platform for functional characterization of stem cell-derived cardi-
omyocytes with applications in cardiotoxicity testing. Stem Cell
Reports 4, 621–631.
Martin, R.L., Lee, J., Cribbs, L.L., Perez-reyes, E., and Hanck, D.A.
(2000). Mibefradil block of cloned T-type calcium channels 1.
J. Pharmacol. Exp. Ther. 295, 302–308.
Millard, D.C., Strock, C.J., Carlson, C.B., Aoyama, N., Juhasz, K.,
Goetze, T.A., Stoelzle-Feix, S., Becker, N., Fertig, N., January, C.T.,
et al. (2016). Identification of drug–drug interactions in vitro: a
case study evaluating the effects of sofosbuvir and amiodarone
on hiPSC-derived cardiomyocytes. Toxicol. Sci. 154, 174–182.
Navarrete, E.G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C.,
Gong, T., Sharma, a., Burridge, P.W., Patlolla, B., Lee, A.S., et al.
(2013). Screening drug-induced arrhythmia events using human
induced pluripotent stem cell-derived cardiomyocytes and low-
impedance microelectrode arrays. Circulation 128, S3–S13.
Pillekamp, F., Haustein,M., Khalil,M., Emmelheinz,M., Nazzal, R.,
Adelmann, R., Nguemo, F., Rubenchyk, O., Pfannkuche, K., Matz-
kies,M., et al. (2012). Contractile properties of early humanembry-
onic stem cell-derived cardiomyocytes: beta-adrenergic stimula-
tion induces positive chronotropy and lusitropy but not
inotropy. Stem Cells Dev. 21, 2111–2121.1572 Stem Cell Reports j Vol. 9 j 1560–1572 j November 14, 2017Pointon, A., Pilling, J., Dorval, T.,Wang, Y., Archer, C., and Pollard,
C. (2016).High-throughput imaging of cardiacmicrotissues for the
assessment of cardiac contraction during drug discovery. Toxicol.
Sci. 155, 444–457.
Ravenscroft, S.M., Pointon, A., Williams, A.W., Cross, M.J., and
Sidaway, J.E. (2016). Cardiac non-myocyte cells show enhanced
pharmacological function suggestive of contractile maturity in
stem cell derived cardiomyocyte microtissues. Toxicol. Sci. 152,
99–112.
Scott, C.W., Zhang, X., Abi-Gerges, N., Lamore, S.D., Abassi, Y.A.,
and Peters, M.F. (2014). An impedance-based cellular assay using
human iPSC-derived cardiomyocytes to quantify modulators of
cardiac contractility. Toxicol. Sci. 142, 331–338.
Serrao, G.W., Turnbull, I.C., Ancukiewicz, D., Kim, D.E., Kao, E.,
Cashman, T.J., Hadri, L., Hajjar, R.J., and Costa, K.D. (2012). Myo-
cyte-depleted engineered cardiac tissues support therapeutic
potential of mesenchymal stem cells. Tissue Eng. Part A 18,
1322–1333.
Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y.-W.,
Funes, C., Rusyn, I., Anson, B., and Cromwell, E.F. (2013).Multipa-
rameter in vitro assessment of compound effects on cardiomyo-
cyte physiology using iPSC cells. J. Biomol. Screen. 18, 39–53.
Steinberg, S.F. (1999). The molecular basis for distinct B-adrenergic
receptor subtype actions in cardiomyocytes. Circ. Res. 85, 1101–
1111.
Turnbull, I.C., Karakikes, I., Serrao, G.W., Backeris, P., Lee, J., Xie,
C., Senyei, G., Gordon, R.E., Li, R.A., Akar, F.G., et al. (2014).
Advancing functional engineered cardiac tissues toward a preclin-
ical model of human myocardium. FASEB J. 28, 644–654.
Weng, Z., Kong, C.-W., Ren, L., Karakikes, I., Geng, L., He, J., Chow,
M.Z.Y., Mok, C.F., Chan, H.Y.S., Webb, S.E., et al. (2014). A simple,
cost-effective but highly efficient system for deriving ventricular
cardiomyocytes from human pluripotent stem cells. Stem Cells
Dev. 23, 1704–1716.
Williams, G.H. (1988). Converting-enzyme inhibitors in the treat-
ment of hypertension. N. Engl. J. Med. 319, 1517–1525.
Wong, B.S., Manabe, N., and Camilleri, M. (2010). Role of pruca-
lopride, a serotonin (5-HT4) receptor agonist, for the treatment
of chronic constipation. Clin. Exp. Gastroenterol. 3, 49–56.
Yang, X., Pabon, L., and Murry, C.E. (2014). Engineering adoles-
cence: maturation of human pluripotent stem cell-derived cardio-
myocytes. Circ. Res. 114, 549–561.
Zhang, D., Shardin, I., Lam, J., Xian, H.-Q., Snodgrass, R., and Bur-
sac, N. (2014). Tissue-engineered cardiac patch for advanced func-
tional maturation of human ESC-derived cardiomyocytes. Bioma-
terials 34, 5813–5820.
Ziupa, D., Beck, J., Franke, G., Feliz, S.P., Hartmann, M., Koren, G.,
Zehender, M., Bode, C., Brunner, M., and Odening, K.E. (2014).
Pronounced effects of HERG-blockers E-4031 and erythromycin
on APD, spatial APD dispersion and triangulation in transgenic
long-QT type 1 rabbits. PLoS One 9, e107210.
